Equillium (NYSE:EQ) Downgraded by Zacks Investment Research to Hold
According to Zacks, “Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company’s product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States. “
Separately, HC Wainwright reaffirmed a buy rating and set a $14.00 target price on shares of Equillium in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $15.00.
Equillium (NYSE:EQ) last posted its earnings results on Monday, August 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04.
A number of institutional investors and hedge funds have recently modified their holdings of EQ. Victory Capital Management Inc. grew its holdings in Equillium by 11.0% in the second quarter. Victory Capital Management Inc. now owns 1,468,727 shares of the company’s stock valued at $8,313,000 after purchasing an additional 145,346 shares during the period. Paloma Partners Management Co acquired a new stake in Equillium in the second quarter valued at approximately $117,000. Edge Wealth Management LLC acquired a new stake in Equillium in the second quarter valued at approximately $40,000. Deutsche Bank AG acquired a new stake in Equillium in the fourth quarter valued at approximately $54,000. Finally, Morgan Stanley grew its holdings in Equillium by 206.0% in the second quarter. Morgan Stanley now owns 6,389 shares of the company’s stock valued at $37,000 after purchasing an additional 4,301 shares during the period.
Equillium Company Profile
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.